Neus Falgas has been working on clinical care and research in the Alzheimer's Unit in Hospital Clínic de Barcelona, Spain. Her work has been focused on evaluating the added value of currently available biomarkers to the clinical diagnosis of early onset Alzheimer's disease (AD) patients as well as in developing strategies that could improve the detection, management and in general, the global health care of early-onset cognitive impairment.
There is a growing interest in developing new tools and measures that allow improved early diagnosis of cognitive deterioration and the development of new drugs. Early onset Alzheimer´s disease frequently has an atypical clinical profile and its clinical features often overlap with other neurodegenerative dementias. This adds to the diagnostic complexity and leads to greater rates of misdiagnosis and diagnostic delay. It is well known that AD diagnostic biomarkers are useful for improving the diagnostic accuracy, especially in early clinical stages or special populations. However, their added value in everyday clinical practice outside academic research centers is still under evaluation. Furthermore, the development of new tools and strategies, or the improvement of existing ones, is necessary to improve the early diagnostic management of these patients.
Falgas thinks there is a wide range of potential improvement on the diagnosis and follow-up of dementia that can be achieved. In this sense, her research is focused in quantifying the added value of the different AD biomarkers (CSF biomarkers and MRI) to the certainty of a clinical diagnosis and she intends to pursue this area of research during her training at GBHI. In her spare time, Falgas loves traveling, going to the theater, reading and jogging.
Bio: Neus Falgas trained as a neurologist at the Hospital Clinic de Barcelona, Spain. In 2016, she received a three-year research grant from the Hospital that allowed her to work as a clinician at the Alzheimer’s disease and other cognitive disorders Unit. For the past three years, she has focused on improving her clinical training in the evaluation and management of the different neurodegenerative dementias as well as finishing a PhD thesis focusing on evaluating the added value of currently available biomarkers to the clinical diagnosis of these subjects.